文献速递肾移植

肾移植受者长期无激素方案联合低剂量他克莫司安全有效

Steroid Avoidance With Low-Dose Tacrolimus is Safe and Effective in the Long-Term for Kidney Transplant Recipients.
PubMed 文献 · Kidney Int Rep · 2025-06-19

SAILOR 研究的长期随访观察显示,免疫低危肾移植受者采用无激素方案(ATG 诱导+低剂量他克莫司+MMF)随访平均 7.3 年,死亡删失移植物存活、患者存活、活检证实的排斥反应发生率及肾功能与含激素方案相似,且按方案人群移植后糖尿病累积发生率显著更低。

要点

  • 无激素方案长期移植物和患者存活与含激素方案相当。
  • 无激素方案不增加活检证实的排斥反应和严重感染风险。
  • 按方案人群移植后糖尿病发生率无激素组显著更低。

核心结论

  • 免疫低危肾移植受者采用无激素方案联合低剂量他克莫司在移植后长达 7 年安全有效。

研究设计与样本

  • SAILOR 长期随访观察性研究,收集原随机对照试验 215 名参与者的临床数据。

主要发现

  • 平均随访 7.3 年,死亡删失移植物存活率无激素组 91.8% 对含激素组 93.1%(P=0.88)。
  • 患者存活率 88% 对 93%(P=0.32),活检证实的排斥反应累积发生率 19.8% 对 16.3%(P=0.6)。
  • eGFR 50.8 对 54 ml/min per 1.73 m2(P=0.27),两组相似。
  • 按方案人群移植后糖尿病累积发生率无激素组显著更低。
  • 需住院的严重感染和恶性肿瘤发生率两组无显著差异,无激素组三分之二参与者末次随访时仍维持无激素方案。

临床怎么用

  • 对免疫低危肾移植受者,可考虑采用 ATG 诱导+低剂量他克莫司+MMF 的无激素方案以降低移植后糖尿病风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In our previous multicenter, open-label, randomized controlled trial (RCT), the SAILOR study, we reported good feasibility, safety, and efficacy of steroid avoidance (SA) at 2 years in immunologically low-risk kidney transplant recipients. A total of 222 participants were randomized to either antithymocyte globulin (ATG) induction + low-dose tacrolimus + mycophenolate mofetil (MMF) or basiliximab induction + low-dose tacrolimus + MMF + prednisolone. Long-term results are needed to confirm the extended safety and efficacy of the SA protocol beyond the short- to medium-term follow-up seen in current reports using low-dose tacrolimus. METHODS: In the SAILOR follow-up observational study, we collected clinical data of 215 participants of the original SAILOR trial at 1, 2, 5 years, and at the last follow-up. RESULTS: The mean follow-up time postrandomization was 7.3 years. Death-censored graft survival (91.8 vs. 93.1%, P = 0.88), patient survival (88 vs. 93%, P = 0.32), cumulative incidence of biopsy-proven rejection (19.8% vs. 16.3%, P = 0.6), and kidney function (estimated glomerular filtration rate [eGFR]: 50.8 vs. 54 ml/min per 1.73 m2, P = 0.27) were similar in the 2 arms. Cumulative incidence of posttransplantation diabetes mellitus in per-protocol population was significantly lower in the steroid-avoidance arm. Serious infections requiring hospitalization, and malignancies did not differ significantly. Two-thirds of participants in the SA arm remained on the steroid-free protocol at the end of follow-up. CONCLUSION: SA proved to be safe and effective in patients with low immunological risk for up to 7 years following kidney transplantation. Our findings provide robust evidence supporting SA strategy with low-dose tacrolimus without compromising outcomes even at the extended 7-years follow up.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Ekberg J, Enevoldsen AA, Wallquist C, et al. Steroid Avoidance With Low-Dose Tacrolimus is Safe and Effective in the Long-Term for Kidney Transplant Recipients. Kidney Int Rep. 2025. PMID: 40980660. doi:10.1016/j.ekir.2025.06.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。